No Detail Found!

Alternate application of all-trans-retinoic acid and arsenic trioxide combined with idarubicin/daunorubicin in treatment of acute promyelocytic leukemia

Author(s)
Xiang Xu Department of Hematology, First Affiliated Hospital of Soochow University,Suzhou,China
Yanqin Mao Department of Hematology, First Affiliated Hospital of Soochow University,Suzhou,China
Xiaming Zhu Department of Hematology, First Affiliated Hospital of Soochow University,Suzhou,China
Fang Tang Department of Hematology, First Affiliated Hospital of Soochow University,Suzhou,China
Abstract
The present study aimed to investigate the efficacy and safety for alternate application of all-trans-retinoic acid (ATRA) and arsenic trioxide (ATO) combined with idarubicin (IDA)/daunorubicin (DNR) in treatment of acute promyelocytic leukemia (APL). a total of 72 ALP patients were divided into the low/medium risk and high risk groups according to the WBC and PLT levels. All APL patients received induction therapy, consolidation therapy and maintenance therapy in treatment under careful nursing monitoring. The complete response (CR) rate was 87.5% (63/72), with 95.12% (39/41) in the low/medium risk group, which was markedly higher than the 77.42% (24/31) high risk group. The PML/RAR a fusion negative rate was also markedly higher in the low/medium risk group (95.12%, 39/41) than the high risk group (77.42%, 24/31). The duration for PML/RAR a fusion negative was also significantly shorter in the low/medium risk group. Recurrence was found in cases in the low/medium risk group, markedly lower than cases in the high risk group. The overall survival (OS) time was markedly longer in low/medium risk patients high. Alternate application of the combination strategy could achieve well CR rate with less complications. And patients with low/medium risk had better clinical outcomes and prognosis than high risk patients.
Publication Details
Page(s) 23-28
Published Journal: Pakistan Journal of Pharmaceutical Sciences, Volume: 35, Issue: 1, Year: 2022

Request the full text from PASTIC

Keywords
Nursing, APL, ATRA, idarubicin/daunorubicin
References
Abaza Y,Kantarjian H,Garcia-Manero G,Estey E,Borthakur G,Jabbour E,Faderl S,O'Brien S,Wierda W,Pierce S W .2017 .Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab. Blood, 129(10) : 1275-1283.
Ader D,Durrani M,Blazar E .2019 .Disseminated intravascular coagulation with purpura fulminans presentation of acute promyelocytic leukemia. CPCEM., 3(4) : 446.
Barragán E,Montesinos P,Camos M,González M,Calasanz MJ,Román-Gómez J,Gómez-Casares MT,Ayala R,López J,Fuster Ó .2011 .Prognostic value of FLT3 mutations in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy. Haematologica, 96(10) : 1470-1477.
Cicconi L,Platzbecker U,Avvisati G,Paoloni F,Thiede C,Vignetti M,Fazi P,Ferrara F,Divona M,Albano F M .2019 .Long-term results of all-trans retinoic acid and arsenic trioxide in non-high-risk acute promyelocytic leukemia: update of the APL0406 Italian-German randomized trial. Leukemia, 34(3) : 914-918.
Creutzig U,Zimmermann M,Bourquin J-P,Dworzak MN,Fleischhack G,Graf N,Klingebiel T,Kremens B,Lehrnbecher T .2013 .Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: results from Study AML-BFM 2004. , 122(1) : 37-43.
Ghavamzadeh A,Alimoghaddam K,Rostami S,Ghaffari SH,Jahani M,Iravani M,Mousavi SA,Bahar B,Jalili M .2011 .Phase II study of single-agent arsenic trioxide for the front-line therapy of acute promyelocytic leukemia. J Clinic Oncol, 29(20) : 2753-2757.
Iland HJ,Bradstock K,Supple SG,Catalano A,Collins M,Hertzberg M,Browett P,Grigg A,Firkin F,Hugman A .2012 .All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4). Blood, 120(8) : 1570-1580.
Kwaan HC,Weiss I,Tallman MS .2019 .The role of abnormal hemostasis and fibrinolysis in morbidity and mortality of acute promyelocytic leukemia. Semin, 45(6) : 612-621.
Lee J-H,Kim H,Joo Y-D and H .2017 .Prospective randomized comparison of idarubicin and high-dose daunorubicin in induction chemotherapy for newly diagnosed acute myeloid leukemia. J. Clin. Oncol., 35(24) : 2754-2763.
Lo-Coco F,Avvisati G,Vignetti M,Thiede C,Orlando SM,Iacobelli S,Ferrara F,Fazi P,Cicconi L,Di Bona E .2013 .Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N. Engl. J. Med, 369 : 111-121.
Lou Y,Qian W,Meng H,Mai W,Tong H,Tong Y,Huang J,Jin J .2013 .High efficacy of arsenic trioxide plus all-trans retinoic acid based induction and maintenance therapy in newly diagnosed acute promyelocytic leukemia. Leukemia Research, 37(1) : 37-42.
Ma Y,Liu L,Jin J,Lou Y .2016 .All-trans retinoic acid plus arsenic trioxide versus all-trans retinoic acid plus chemotherapy for newly diagnosed acute promyelocytic leukemia: A meta-analysis. PloS one, 11(7) : e0158760.
Noguera NI,Catalano G,Banella C,Divona M,Faraoni I,Ottone T,Arcese W,Voso MT .2019 .Acute promyelocytic leukemia: Update on the mechanisms of leukemogenesis, resistance and on innovative treatment strategies. Cancers, 11(10) : 1591.
Ohtake S,Miyawaki S,Fujita H,Kiyoi H,Shinagawa K,Usui N,Okumura H,Miyamura K,Nakaseko C,Miyazaki Y C .2011 .Randomized study of induction therapy comparing standard-dose idarubicin with highdose daunorubicin in adult patients with previously untreated acute myeloid leukemia: The JALSG AML201 Study. , 117(8) : 2358-2365.
Orfali N,O'Donovan TR,Cahill MR,Benjamin D,Nanus DM,McKenna SL,Gudas LJ,Mongan NP .2020 .All‐trans retinoic acid (ATRA)‐induced TFEB expression is required for myeloid differentiation in acute promyelocytic leukemia (APL). Eur. J. Haematol., 104(3) : 236-250.
Park JH,Qiao B,Panageas KS,Schymura MJ,Jurcic JG,Rosenblat TL,Altman JK,Douer D,Rowe JM,Tallman MS JM .2011 .Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid. Blood, 118(5) : 1248-1254.
Ravandi F,Estey E,Jones D,Faderl S,Kantarjian H S .2009 .Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. J. Clin. Oncol., 27(4) : 504-510.
Sanz MA,Fenaux P,Tallman MS,Estey EH,Löwenberg B,Naoe T,Lengfelder E,Döhner H,Burnett AK,Chen S-J .2019 .Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. , 133(15) : 1630-1643.
Sanz MA,Montesinos P .2020 .Advances in the management of coagulopathy in acute promyelocytic leukemia. Thromb. Res, 191 : S63-S67.
Sanz MA,Montesinos P,Kim HT,Ruiz-Argüelles GJ,Undurraga MS,Uriarte MR,Martínez L,Jacomo RH,Gutiérrez-Aguirre H,Melo RAM H .2015 .All-trans retinoic acid with daunorubicin or idarubicin for riskadapted treatment of acute promyelocytic leukaemia: A matched-pair analysis of the PETHEMA LPA-2005 and IC-APL studies. , 94(8) : 1347-1356.
Tomita A,Kiyoi H,Naoe T H .2013 .Mechanisms of action and resistance to all-trans retinoic acid (ATRA) and arsenic trioxide (As 2 O 3) in acute promyelocytic leukemia. Int. J. Hematol., 97(6) : 717-725.
Zhao J,Liang J-W,Xue H-L,Shen S-H,Chen J,Tang YJ,Yu L-S,Liang H-H J-Y .2019 .The genetics and clinical characteristics of children morphologically diagnosed as acute promyelocytic leukemia. Leukemia, 33(6) : 1387-1399.
0

Citations

0

Downloads

96

Views